3 Solar Modules Maker, Specialty Medicines Company and IT Engineering Services Company Stocks With a Strong Future Roadmap: Emmvee Photovoltaic Power, Ajanta Pharma and Mindteck (India)

Solar panel, branded pharma and IT stocks offer a focused view of a sector where demand keeps widening. Emmvee Photovoltaic Power, Ajanta Pharma and Mindteck (India) cover a solar modules maker, a branded pharmaceuticals company and an IT services company.

This list covers three solar panel, branded pharma and IT stocks with complete current figures: Emmvee Photovoltaic Power, Ajanta Pharma and Mindteck (India). Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Solar Panel, Branded Pharma and IT Stocks?

Solar panel, branded pharma and IT stocks are listed companies that make solar cells and modules for utilities, factories and homes, develop and sell branded medicines for eye, skin, heart and pain care, and provide software and engineering services to global clients. Their earnings depend on solar installations, prescription demand and client technology budgets.

Solar Panel, Branded Pharma and IT Stocks at a Glance

On valuation, Emmvee Photovoltaic Power and Mindteck (India) trade at a P/E below the industry P/E, while Ajanta Pharma trades above it, which reflects the growth the market already expects. Readers comparing solar panel, branded pharma and IT stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Solar Panel, Branded Pharma and IT Stocks Have a Strong Roadmap in India?

Solar panel, branded pharma and IT stocks have a strong roadmap in India because rapid solar capacity additions, steady demand for specialty medicines and wider outsourcing of technology work keep widening the market for these companies.

• Solar modules. Utilities and homes add clean energy fast.
• Branded pharma. Doctors prescribe trusted specialty brands.
• IT services. Clients outsource engineering and software work.

Why Emmvee Photovoltaic Power Features Among These Solar Panel, Branded Pharma and IT Stocks

Among the solar panel, branded pharma and IT stocks on this list, Emmvee Photovoltaic Power is a Bengaluru-based manufacturer of solar photovoltaic modules and solar cells for utility-scale, commercial and rooftop customers.

Revenue rose from Rs 567 crore in FY22 to Rs 5,103 crore in FY26, a compound annual growth rate of 73.2%. Net profit for FY26 was Rs 1,082 crore, a net margin of 21.2%.

The company has a return on equity of 32.3%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 16,672 crore. The stock trades at a P/E of 11.8, below the industry P/E of 40.7.

Roadmap: The company is expanding module and cell capacity to serve India's rising solar installations and is moving toward a more integrated manufacturing chain. Policy support for locally made solar equipment helps its order flow.

What to watch: Follow capacity commissioning, order inflows and solar policy changes.

Why Ajanta Pharma Features Among These Solar Panel, Branded Pharma and IT Stocks

Among the photovoltaic, prescription brand and software shares on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.

In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%.

Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0.

Roadmap: The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.

What to watch: Monitor the pace of new launches in branded markets and the momentum in the United States generics business.

Why Mindteck (India) Features Among These Solar Panel, Branded Pharma and IT Stocks

Among the three companies on this list, Mindteck (India) provides IT services including software development, data and analytics and cloud support to clients across healthcare, financial services and other industries.

The company has a return on equity of 10.4%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 436 crore. The stock trades at a P/E of 14.0, below the industry P/E of 17.6.

Revenue rose from Rs 304 crore in FY22 to Rs 417 crore in FY26, a compound annual growth rate of 8.3%. Net profit grew from Rs 20.8 crore in FY23 to Rs 31.5 crore in FY26, which works out to a compound annual growth rate of 14.9%. In the June 2026 quarter, revenue grew 2.8% year on year to Rs 107 crore.

Roadmap: The company is focusing on digital engineering, data and cloud services for existing clients and widening its work in specialised industries. Long client relationships support steady project flow.

What to watch: Monitor client additions, utilisation and currency movements.

Emmvee Photovoltaic Power vs Ajanta Pharma vs Mindteck (India) on Key Financials

The table below sets the three solar panel, branded pharma and IT stocks side by side on revenue, profit and margin, using reported figures.

Emmvee Photovoltaic Power posts the highest return on equity in this group at 32.3%. Ajanta Pharma has the largest FY26 revenue at Rs 5,625 crore, and Emmvee Photovoltaic Power shows the fastest revenue growth with a 73.2% compound annual rate. A useful habit with solar panel, branded pharma and IT stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Solar Panel, Branded Pharma and IT Stocks

Every theme carries risks that deserve a check before any decision. For these solar panel, branded pharma and IT stocks, the main points are: Long-term photovoltaic, prescription brand and software shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Module prices. Solar equipment prices and policy support can change returns.
• Pricing pressure. Generic prices can change by market.
• Client budgets. Spending can vary with global conditions.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter solar panel, branded pharma and IT stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Solar Panel, Branded Pharma and IT Stocks

Solar panel, branded pharma and IT stocks reward patient research into demand, execution and financial strength. Emmvee Photovoltaic Power, Ajanta Pharma and Mindteck (India) each have a clear plan to grow. Based on the 11 November 2026 close, Emmvee Photovoltaic Power trades at Rs 265.8, Ajanta Pharma at Rs 3,319.6 and Mindteck (India) at Rs 137.31.

Download the Univest iOS App or Univest Android App to track solar panel, branded pharma and IT stocks, set price alerts and get research-backed stock ideas.

What are solar panel, branded pharma and IT stocks?

Ans. Solar panel, branded pharma and IT stocks are listed companies that make solar cells and modules for utilities, factories and homes, develop and sell branded medicines for eye, skin, heart and pain care, and provide software and engineering services to global clients. Their earnings depend on solar installations, prescription demand and client technology budgets. This list looks at three of them, Emmvee Photovoltaic Power, Ajanta Pharma and Mindteck (India), using reported FY22 to FY26 financials and the 11 November 2026 closing prices.

Which solar panel, branded pharma and IT stocks are covered in this list?

Ans. This list covers Emmvee Photovoltaic Power, Ajanta Pharma and Mindteck (India). Based on the 11 November 2026 close, Emmvee Photovoltaic Power traded at Rs 265.8, Ajanta Pharma at Rs 3,319.6 and Mindteck (India) at Rs 137.31. Their return on equity ranges from 10.4% to 32.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.3% to 73.2%.

Why do solar panel, branded pharma and IT stocks have a strong future roadmap in India?

Ans. Solar panel, branded pharma and IT stocks have a strong roadmap in India because rapid solar capacity additions, steady demand for specialty medicines and wider outsourcing of technology work keep widening the market for these companies. The main drivers are as follows. Solar modules. Utilities and homes add clean energy fast. Branded pharma. Doctors prescribe trusted specialty brands. IT services. Clients outsource engineering and software work. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Emmvee Photovoltaic Power performed financially?

Ans. Revenue rose from Rs 567 crore in FY22 to Rs 5,103 crore in FY26, a compound annual growth rate of 73.2%. Net profit for FY26 was Rs 1,082 crore, a net margin of 21.2%. The company has a return on equity of 32.3%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 16,672 crore. The stock trades at a P/E of 11.8, below the industry P/E of 40.7. Looking ahead, the company is expanding module and cell capacity to serve India's rising solar installations and is moving toward a more integrated manufacturing chain. Policy support for locally made solar equipment helps its order flow.

How has Ajanta Pharma performed financially?

Ans. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.

How has Mindteck (India) performed financially?

Ans. Revenue rose from Rs 304 crore in FY22 to Rs 417 crore in FY26, a compound annual growth rate of 8.3%. Net profit grew from Rs 20.8 crore in FY23 to Rs 31.5 crore in FY26, which works out to a compound annual growth rate of 14.9%. In the June 2026 quarter, revenue grew 2.8% year on year to Rs 107 crore. The company has a return on equity of 10.4%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 436 crore. The stock trades at a P/E of 14.0, below the industry P/E of 17.6. Looking ahead, the company is focusing on digital engineering, data and cloud services for existing clients and widening its work in specialised industries. Long client relationships support steady project flow.

What risks should investors check before buying solar panel, branded pharma and IT stocks?

Ans. Investors should check a few risks before buying solar panel, branded pharma and IT stocks. Module prices. Solar equipment prices and policy support can change returns. Pricing pressure. Generic prices can change by market. Client budgets. Spending can vary with global conditions. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of solar panel, branded pharma and IT stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.